Incyte Corporation
Incyte is a U.S.-based biopharmaceutical company that discovers, develops, and commercializes proprietary medicines. Its business is concentrated in hematology, oncology, and inflammation/autoimmunity, with revenue driven by marketed drugs such as JAKAFI, OPZELURA, MONJUVI/MINJUVI, and NIKTIMVO plus royalties and collaboration income.
Fiscal year 2025 · change from previous year
Development 2020–2025
Business
Share of revenueApproved medicines for myelofibrosis, polycythemia vera, GVHD, and related blood cancers.
Topical and systemic therapies for inflammatory skin and immune-mediated diseases.
Royalties earned from partnered products sold by collaborators in certain markets.
Upfront, milestone, and other collaboration-related revenue from partnered R&D programs.
Products
Reported · share of revenue- JAKAFI60.2 %
- OPZELURA13.2 %
- JAKAVI Royalty Revenues8.9 %
- NIKTIMVO2.9 %
- Milestone and Contract Revenues2.9 %
- Other11.9 %
Source: 10-K FY2025, revenue the company reports per product line (SEC XBRL). Shares are of the lines shown and add up to 100 %.
Customers
Incyte sells primarily to specialty and retail pharmacies, specialty distributors, wholesalers, hospital pharmacies, and an exclusive wholesaler outside the U.S. The end users are patients treated by hematologists, oncologists, dermatologists, transplant specialists, and other physicians managing rare cancers and immune-mediated diseases.
Buy and dispense Incyte's branded medicines, especially chronic therapies like JAKAFI and OPZELURA.
Purchase therapies used in GVHD and oncology settings where administration and reimbursement are hospital-linked.
Prescribe Incyte's medicines to patients with hematologic malignancies, GVHD, and inflammatory skin disease.
Commercialize partnered assets in certain geographies and pay royalties or milestones to Incyte.
Strategy
Incyte's strategy is to develop and commercialize internally discovered or in-licensed therapies in markets where it can compete effectively, while using partnerships to extend reach where it lacks scale or expertise. The company is also expanding its commercial infrastructure outside the U.S. to support recent launches and broaden the contribution from ex-U.S. markets.
More indications and more geographies increase the lifetime value of each asset.
Pipeline success is needed to offset eventual patent expiry and sustain growth.
Partners can provide local expertise, funding, and commercialization scale.
Geography
Incyte is globally organized, with headquarters and commercial operations in Wilmington, Delaware, plus major regional hubs in Morges, Switzerland, Tokyo, and Montreal. The company reported that 70% of employees were based in the U.S. and Canada, 27% in Europe, and 3% in Asia, reflecting a business that is operationally global but still anchored in North America and Europe.
Risks
Incyte faces typical biopharma risks around clinical trial failure, regulatory approval, patent protection, and product liability, but also company-specific dependence on a small number of marketed products. Manufacturing complexity, especially for antibody-based products, and reliance on third-party contract manufacturers can disrupt supply and delay launches or approvals.
- Clinical development and regulatory riskImpact: HighLikelihood: High
Pipeline assets require successful trials and approvals, and failures can remove expected future revenue streams.
Exposure - Manufacturing and third-party supply riskImpact: HighLikelihood: Medium
Antibody manufacturing is complex and depends on contract manufacturers and regulatory approvals for facilities.
Exposure: Biologics and antibody products
- Patent and exclusivity erosionImpact: HighLikelihood: Low
Loss of patent protection or successful challenges can reduce pricing power and royalty value.
Exposure: JAKAFI and other proprietary assets
- Concentration in a limited set of commercial productsImpact: High
A large share of revenue comes from a small number of therapies, so any demand slowdown or competition can materially affect results.
Exposure - Product liability and safety perceptionImpact: MediumLikelihood: Medium
Adverse events or perceived safety issues can reduce prescribing and trigger claims or label restrictions.
Exposure: All marketed medicines
Accounting
Judgemental itemsNet sales are reduced by estimated rebates, returns, chargebacks, and co-pay support, which can materially affect reported revenue.
Impact: Affects product revenue and gross-to-net trends
Revenue is recorded when control transfers, so shipment timing and channel inventory changes affect quarterly comparability.
Impact: Can create quarter-to-quarter volatility
Partner sales, milestones, and licensing terms can create uneven revenue patterns and judgment around timing.
Impact: Affects non-product revenue mix
Biopharma litigation, safety, and regulatory matters can require accruals or disclosures based on judgment.
Impact: Can affect operating expenses and reserves
Similar listed companies
Publicly listed companies with a comparable business focus.
Innate Pharma SA
IPHYF · Biological Products, (No Diagnostic Substances)
Innate Pharma SA is a French clinical-stage biotechnology company focused on developing immunotherapies for cancer.
Enanta Pharmaceuticals, Inc
ENTA · Pharmaceutical Preparations
Enanta Pharmaceuticals is a U.S.-based biotechnology company focused on discovering and developing small-molecule drugs in virology and immunology.
Arcutis Biotherapeutics, Inc.
ARQT · Pharmaceutical Preparations
Arcutis Biotherapeutics is a U.S.-based commercial-stage biopharmaceutical company focused on dermatology.
Intensity Therapeutics, Inc
INTS · Biological Products, (No Diagnostic Substances)
Aclaris Therapeutics, Inc.
ACRS · Pharmaceutical Preparations
Aclaris Therapeutics is a clinical-stage biopharmaceutical company focused on discovering and developing small and large molecule therapies for immuno-inflammatory diseases.
Vaxcyte, Inc.
PCVX · Biological Products, (No Diagnostic Substances)
Last updated: 24/09/2026